London, May 9, 2026, 16:11 (BST)
- Haleon shares closed at 331.20 pence on May 8, down 1.16%, on volume of about 39.7 million shares.
- The company published a routine update to its £10 billion Euro Medium Term Note programme on May 7.
- Haleon kept its 2026 outlook after first-quarter organic revenue grew 2.2%, held back by a weak cold and flu season.
Haleon PLC ended the week lower in London, with the Sensodyne and Panadol maker’s latest market disclosures putting attention back on its funding headroom, share buyback and slower first-quarter growth.
The timing matters. Haleon is trying to show investors that a soft cold and flu season was a passing drag, not a deeper demand problem, while it keeps returning cash through buybacks and maintains access to debt markets.
The shares closed at 331.20 pence on Friday, down 1.16%, after opening at 337.20 pence and trading as low as 329.30 pence, Investing.com data showed. The stock remains well below its 52-week high, with the same data showing a year range of 325.10 pence to 419.40 pence.
Haleon said on May 7 it had published listing particulars for Haleon UK Capital plc’s and Haleon Netherlands Capital B.V.’s £10 billion Euro Medium Term Note programme, guaranteed by the parent company. An EMTN programme is a standing bond framework that lets a company issue debt over time; the update does not mean Haleon has drawn the full amount.
The filing landed in the same week Haleon reported further share purchases. A U.S. SEC filing showed the company bought 12,171,987 ordinary shares for cancellation under its buyback programme, with trades made between April 27 and May 1 across the London Stock Exchange, CBOE UK venues and Aquis.
After those transactions settle, Haleon said its ordinary shares with voting rights would stand at 8,878,226,798. Share buybacks cut the share count and can lift per-share measures, but they also use cash that could otherwise go toward debt reduction, investment or deals.
Haleon has allocated £500 million to share buybacks in 2026, with about 36% completed at the end of the first quarter. The company also reiterated its full-year target for 3% to 5% organic revenue growth, a measure that strips out currency moves and portfolio changes, and high-single-digit adjusted operating profit growth at constant currency.
First-quarter reported revenue was £2.86 billion, almost flat on a reported basis. Organic revenue rose 2.2%, with price up 2.4% and volume down 0.2%; Haleon estimated the weak cold and flu season cut growth by about 130 basis points, or 1.3 percentage points. Oral Health grew 8.3%, helped by Sensodyne and parodontax, while Respiratory Health fell 3.4%.
Chief Executive Brian McNamara called the quarter a “competitive performance in a challenging market” and said Haleon expected growth “to accelerate across the balance of the year.” The company pointed to North America returning to organic growth and continued oral-care strength, but the reliance on a few stronger categories is still plain. Haleon Corporate
Cost pressure is another watch point. Reuters reported on April 29 that Haleon had warned of rising freight costs linked to the Iran conflict, with Procter & Gamble and Reckitt also facing pressure from higher energy and freight costs. “We started to see surcharges on freight, quite small, but I would expect that to increase,” Chief Financial Officer Dawn Allen told analysts. Reuters
McNamara also told analysts consumer spending in the Middle East, which accounts for about 5% of Haleon’s revenue, was down by a low-double-digit percentage, Reuters reported. He said the company could “tweak” pricing if opportunities arose, while fixed-price contracts and hedging were helping contain costs. Reuters
One sell-side view remains constructive. Jefferies analyst David Hayes said Haleon could do more to show the underlying growth rate once cold and flu volatility is stripped out; Jefferies kept a Buy rating but cut its target price to 400 pence from 450 pence, Proactive Investors reported earlier this week.
But the recovery is not locked in. Another weak illness season, higher freight costs, softer U.S. consumer spending or weaker Middle East demand could leave Haleon leaning harder on price, cost savings and buybacks than on volume growth.
The next scheduled test is the half-year result on July 30, followed by a third-quarter trading statement on October 29. Investors will be looking for proof that North America is improving and that Oral Health is not doing too much of the work.
